cosibelimab   Click here for help

GtoPdb Ligand ID: 13676

Synonyms: CK-301 | CK301 | cosibelimab-ipdl | Unloxcyt®
Approved drug
cosibelimab is an approved drug (FDA (2024))
Compound class: Antibody
Comment: Cosibelimab (CK-301) is a human anti-programmed cell death 1 ligand 1 (PD-L1) monoclonal antibody. It belongs to the immune checkpoint inhibitor class of anti-tumour drugs. Cosibelimab blocks inhibitory PD-L1 regulation of the anti-tumour immune response and induces antibody-dependent cell-mediated cytotoxicity (ADCC).
Peptide sequence alignments indicate identity between peptide sequences for the INN cosibelimab and those for antibody CTI-48 as claimed in patent US10590199B2 [1].
No information available.
Summary of Clinical Use Click here for help
The FDA approved cosibelimab in December 2024, to treat metastatic/locally advanced cutaneous squamous cell carcinoma. At the time of approval, cosibelimab was the first and only anti-PD-L1 therapeutic authorised for use in this indication.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03212404 Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Phase 1 Interventional Checkpoint Therapeutics, Inc. 2